Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
Conditions
Keywords
Colon Cancer, Lung Cancer, Breast Cancer, CEA, Prostate Cancer
Brief summary
The purpose of this study is to find out what effects (good and bad) that a cancer vaccine has on you and your cancer. The cancer vaccine is called Ad5 \[E1-, E2b-\]-CEA(6D)or ETBX-011 and is made by Etubics. This vaccine is based on a virus called an adenovirus but it has been changed to express the protein CEA that is found on some cancer cells. Therefore, the vaccine can tell the immune system to attack cancer cells which make CEA. The investigators are trying to determine whether giving this virus is safe and whether this causes a strong immune system attack on the cancer. ETBX-011 is an investigational drug.
Detailed description
This is a phase I/II study with the primary purpose to determine the safety of immunization with Ad5 \[E1-, E2B-\]-CEA(6D), in patients with advanced or metastatic CEA-expressing malignancies. The secondary objectives are to evaluate CEA-specific immune responses to the immunizations and to obtain preliminary data on clinical response rate. The study population consists of patients with a histologically confirmed diagnosis of metastatic malignancy that is CEA positive who were previously treated with standard therapy known to have a possible survival benefit or refused such therapy. The study will determine the safety of three dosage levels of Ad5 \[E1-, E2B-\]-CEA(6D) vaccine (phase I component), and the maximally tolerated dose of Ad5 \[E1-, E2B-\]-CEA(6D) vaccine (phase II component). The study drug is Ad5 \[E1-, E2B-\]-CEA(6D) given by subcutaneous (SQ) injection every 3 weeks for 3 immunizations. We will evaluate safety in each cohort at least 3 weeks after the last patient in the previous cohort has received their first injection. A dosing scheme will be considered safe if \<33% of patients treated at a dosage level experience DLT (e.g., 0 of 3, ≤1 of 6, ≤3 of 12 or ≤5 of 18 patients). We are currently enrolling up to 10 additional patients (Cohort 6) to evaluate safety, immunogenicity, and efficacy at the highest dose of vaccine.
Interventions
BIOLOGICALAd5 CEA Vaccine
Ad5 \[E1-, E2b-\]-CEA(6D) Vector Vaccine
Sponsors
NantCell, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed diagnosis of malignancy expressing CEA. Because this is a safety and immunogenicity study, patients are NOT required to have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST). 2. For all tumor types other than colorectal, the tumor must express CEA as defined by immunohistochemical staining (at least 50% of the tumor with at least moderate intensity of staining) or a tumor known to be universally CEA positive (i.e. colon and rectal cancer). If colorectal cancer then, pathologic or clinical confirmation of adenocarcinoma is required. 3. Patients must have received treatment with standard therapy known to have a possible overall survival benefit. For the following common cancers, the following eligibility criteria apply: * Colorectal cancer: Must have received and progressed through at least one line of palliative chemotherapy consisting of one of the following regimens: * Palliative chemotherapy for metastatic colorectal cancer with 5 fluorouracil (or capecitabine) and oxaliplatin. * Palliative chemotherapy for metastatic colorectal cancer with 5 fluorouracil (or capecitabine) and irinotecan. * Palliative chemotherapy regimen for metastatic colorectal cancer that includes bevacizumab. * Colorectal cancer patients currently receiving palliative single-agent bevacizumab or cetuximab will be eligible for this trial and may continue these therapies concomitant with study treatment (if they have been on these single agent therapies for at least 3 months). * Breast cancer: Must have received and progressed through at least one line of chemotherapy for metastatic breast cancer consisting of one of the following regimens: * Palliative anthracycline- or taxane-based chemotherapy * Patients with tumors that over express HER2 (IHC 3+ or FISH+) must have received and progressed through at least one line of palliative therapy that combines trastuzumab with chemotherapy. * Breast cancer patients currently receiving palliative endocrine therapy or single-agent trastuzumab will be eligible for this trial and may continue these therapies concomitant with study treatment (if they have been on these single agent therapies for at least 3 months). * Patients who have been treated or offered the options of treatment with Bevacizumab (option clearly stated in the consent form). * Patients who have been treated or offered the options of treatment with Lapatinib (option clearly stated in the consent form). * Lung cancer: Must have received and progressed through chemotherapy for metastatic disease consisting of one of the following regimens: * Palliative platinum-based (cisplatin or carboplatin) chemotherapy if the patient has not received chemotherapy previously. * Palliative taxane-based (docetaxel or paclitaxel) or vinorelbine chemotherapy if the patient has received chemotherapy previously. * Lung cancer patients currently receiving palliative single-agent erlotinib or gefitinib will be eligible for this trial and may continue these therapies concomitant with study treatment (if they have been on these single agent therapies for at least 3 months). * Pancreatic cancer: Must have received and progressed through chemotherapy including gemcitabine. \- Pancreatic cancer patients currently receiving palliative single-agent erlotinib will be eligible for this trial and may continue this therapy concomitant with study treatment (if they have been on this single agent therapy for at least 3 months). * For other malignancies, if a first line therapy with survival or palliative benefit exists, it should have been administered and there should have been progressive disease. * Patients who have received and progressed through first-line palliative chemotherapy must be advised regarding second-line therapy before being enrolled on this investigational study. 4. Karnofsky performance score of 70% or higher 5. Estimated life expectancy \> 3 months 6. Age ≥ 21 years, but \< 75 7. Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR \<1.5, PTT \<1.5X ULN 8. Adequate renal and hepatic function, with serum creatinine \< 1.5 mg/dL, bilirubin \< 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal. 9. Patients who have received prior CEA-targeted immunotherapy are eligible for this trial, if this treatment was discontinued at least 3 months prior to enrollment. 10. Patients who are taking medications that do not have a known history of immunosuppression are eligible for this trial. 11. Ability to understand and provide signed informed consent that fulfills Institutional Review Board's guidelines. 12. Ability to return to the clinical site for adequate follow-up, as required by this protocol.
Exclusion criteria
1. Patients with concurrent cytotoxic chemotherapy or radiation therapy should be excluded. There are no exclusions based on the number of prior chemotherapy, biologic, hormonal, or experimental regimens. Except for the permitted concomitant therapies (bevacizumab, cetuximab, trastuzumab, erlotinib, gefitinib, or hormonal therapy which patients must have been on for at least 3 months at the time of enrollment if they intend to continue them with the vaccine), there must be at least 3 months between any prior CEA-targeted immunotherapy and study treatment and at least 4 weeks between any other prior therapy (including radiotherapy) and study treatment. Patients must have recovered to grade 1 acute toxicities from prior treatment. 2. Patients with a history of or current brain metastases will not be permitted. 3. Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted. 4. Patients with serious intercurrent chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment. 5. Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded. 6. Concurrent (or within the last 5 years) second malignancy other than non melanoma skin cancer, cervical carcinoma in situ, controlled superficial bladder cancer, or other carcinoma in situ that has been treated. 7. Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immunosuppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections. 8. Patients on steroid therapy (or other immunosuppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies) prior to enrollment. 9. Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study. 10. Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded. 11. Patients will be allowed warfarin 1mg po qd other than for port prophylaxis. 12. Patients with metastatic disease which is determined to be resectable will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities | Every 3 weeks for 9 weeks and every 3 months for 1 year | The primary objective of this protocol is to determine the safety of immunization with Ad5 \[E1-, E2b-\]-CEA(6D) in patients with advanced or metastatic CEA-expressing malignancies. A dosing scheme will be considered safe if \<33% of patients treated at a dosage level experience DLT (e.g., 0 of 3, ≤1 of 6, ≤3 of 12 or ≤5 of 18 patients). |
| Number of Participants With Adverse Events | from the time of first dose to the 30 days past last dose of study drug, up to 330 days | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Response Rate | from first dose up to a year follow up | Clinical response was assessed for participants that achieve a clinical response of complete response (CR) or partial response (PR), according to RECISIT criteria (v1.0 for Cohorts 1-5 and v1.1 for Cohort 6). CR is defined as disappearance of all target lesions. PR is defined as \>=30% decrease in the sum of the longest diameter of target lesions. |
| Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Baseline (Week 0) up to Week 9 | Cell mediated immune response was characterized using ELISpot assays performed on Peripheral Blood Mononuclear Cells to determine the number of IFN-gamma secreting cells. |
| CEA Antibody (ng/mL) by Visit | Baseline (Week 0) to Week 9 | Summary of CEA Antibody (ng/mL) by Visit |
Countries
United States
Participant flow
Pre-assignment details
Endpoints were tabulated as planned for the 43 patients by cohorts.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 1x10\^9 VP (0.5 mL) | 3 |
| Cohort 2 1x10\^10 VP (0.5 mL) | 4 |
| Cohort 3 1x10\^11 VP (0.5 mL) | 7 |
| Cohort 4 (Phase II Cohort at MTD): Ad5 \[E1-, E2b-\]-CEA(6D) at a dose of 1 x 10\^11 particles | 14 |
| Cohort 5 5x10\^11 VP (2.5 mL) | 6 |
| Cohort 6 5x10\^11 VP (1.0 mL) | 9 |
| Total | 43 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Administration Of Alternative Therapy | 0 | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Death | 0 | 0 | 1 | 1 | 0 | 2 |
| Overall Study | Other | 0 | 0 | 0 | 3 | 1 | 0 |
| Overall Study | Progressive Disease | 3 | 3 | 5 | 9 | 5 | 5 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Cohort 1 | Total | Cohort 6 | Cohort 5 | Cohort 4 | Cohort 3 | Cohort 2 |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 61.0 years STANDARD_DEVIATION 7.21 | 58.8 years STANDARD_DEVIATION 8.56 | 62.1 years STANDARD_DEVIATION 7.46 | 55.5 years STANDARD_DEVIATION 11.86 | 61.7 years STANDARD_DEVIATION 8.31 | 54.0 years STANDARD_DEVIATION 4.8 | 52.8 years STANDARD_DEVIATION 7.8 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 40 Participants | 9 Participants | 6 Participants | 11 Participants | 7 Participants | 4 Participants |
| Sex: Female, Male Female | 1 Participants | 20 Participants | 7 Participants | 3 Participants | 5 Participants | 3 Participants | 1 Participants |
| Sex: Female, Male Male | 2 Participants | 23 Participants | 2 Participants | 3 Participants | 9 Participants | 4 Participants | 3 Participants |
| Subjects with advanced or metastatic malignancies expressing CEA | 3 Participants | 43 Participants | 9 Participants | 6 Participants | 14 Participants | 7 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 3 | 3 / 4 | 6 / 7 | 8 / 14 | 4 / 6 | 7 / 9 |
| other Total, other adverse events | 2 / 3 | 3 / 4 | 6 / 7 | 10 / 14 | 6 / 6 | 9 / 9 |
| serious Total, serious adverse events | 0 / 3 | 1 / 4 | 2 / 7 | 1 / 14 | 1 / 6 | 2 / 9 |
Outcome results
Primary
Number of Participants With Adverse Events
Time frame: from the time of first dose to the 30 days past last dose of study drug, up to 330 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 | Number of Participants With Adverse Events | 2 Participants |
| Cohort 2 | Number of Participants With Adverse Events | 3 Participants |
| Cohort 3 | Number of Participants With Adverse Events | 6 Participants |
| Cohort 4 | Number of Participants With Adverse Events | 10 Participants |
| Cohort 5 | Number of Participants With Adverse Events | 6 Participants |
| Cohort 6 | Number of Participants With Adverse Events | 9 Participants |
Primary
Number of Participants With Dose Limiting Toxicities
The primary objective of this protocol is to determine the safety of immunization with Ad5 \[E1-, E2b-\]-CEA(6D) in patients with advanced or metastatic CEA-expressing malignancies. A dosing scheme will be considered safe if \<33% of patients treated at a dosage level experience DLT (e.g., 0 of 3, ≤1 of 6, ≤3 of 12 or ≤5 of 18 patients).
Time frame: Every 3 weeks for 9 weeks and every 3 months for 1 year
Population: Safety population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 | Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Cohort 2 | Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Cohort 3 | Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Cohort 4 | Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Cohort 5 | Number of Participants With Dose Limiting Toxicities | 0 Participants |
| Cohort 6 | Number of Participants With Dose Limiting Toxicities | 0 Participants |
Secondary
CEA Antibody (ng/mL) by Visit
Summary of CEA Antibody (ng/mL) by Visit
Time frame: Baseline (Week 0) to Week 9
Population: Safety Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1 | CEA Antibody (ng/mL) by Visit | Baseline | 0.0470 ng/mL | Standard Deviation 0.02291 |
| Cohort 1 | CEA Antibody (ng/mL) by Visit | Week 9 | 0.0760 ng/mL | Standard Deviation 0.11953 |
| Cohort 2 | CEA Antibody (ng/mL) by Visit | Baseline | 0.0310 ng/mL | Standard Deviation 0.004 |
| Cohort 2 | CEA Antibody (ng/mL) by Visit | Week 9 | 0.0307 ng/mL | Standard Deviation 0.01106 |
| Cohort 3 | CEA Antibody (ng/mL) by Visit | Baseline | 0.0690 ng/mL | Standard Deviation 0.09319 |
| Cohort 3 | CEA Antibody (ng/mL) by Visit | Week 9 | 0.1157 ng/mL | Standard Deviation 0.10571 |
| Cohort 4 | CEA Antibody (ng/mL) by Visit | Baseline | 0.0709 ng/mL | Standard Deviation 0.09117 |
| Cohort 4 | CEA Antibody (ng/mL) by Visit | Week 9 | 0.0439 ng/mL | Standard Deviation 0.05536 |
| Cohort 5 | CEA Antibody (ng/mL) by Visit | Baseline | 0.3193 ng/mL | Standard Deviation 0.21676 |
| Cohort 5 | CEA Antibody (ng/mL) by Visit | Week 9 | 0.3665 ng/mL | Standard Deviation 0.19723 |
| Cohort 6 | CEA Antibody (ng/mL) by Visit | Baseline | 0 ng/mL | Standard Deviation 0 |
| Cohort 6 | CEA Antibody (ng/mL) by Visit | Week 9 | 0 ng/mL | Standard Deviation 0 |
Secondary
Clinical Response Rate
Clinical response was assessed for participants that achieve a clinical response of complete response (CR) or partial response (PR), according to RECISIT criteria (v1.0 for Cohorts 1-5 and v1.1 for Cohort 6). CR is defined as disappearance of all target lesions. PR is defined as \>=30% decrease in the sum of the longest diameter of target lesions.
Time frame: from first dose up to a year follow up
Population: Safety Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 | Clinical Response Rate | 0 Participants |
| Cohort 2 | Clinical Response Rate | 0 Participants |
| Cohort 3 | Clinical Response Rate | 0 Participants |
| Cohort 4 | Clinical Response Rate | 0 Participants |
| Cohort 5 | Clinical Response Rate | 0 Participants |
| Cohort 6 | Clinical Response Rate | 0 Participants |
Secondary
Immune Response Against CEA - IFN-gamma Secreting Cells by Visit
Cell mediated immune response was characterized using ELISpot assays performed on Peripheral Blood Mononuclear Cells to determine the number of IFN-gamma secreting cells.
Time frame: Baseline (Week 0) up to Week 9
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 3 | 6.7 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 5.77 |
| Cohort 1 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 9 | 0.0 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 0 |
| Cohort 1 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Baseline | 1.0 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 1.73 |
| Cohort 1 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 6 | 16.0 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 23.52 |
| Cohort 2 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 3 | 26.3 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 43.04 |
| Cohort 2 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 6 | 1.7 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 2.89 |
| Cohort 2 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 9 | 13.3 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 23.09 |
| Cohort 2 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Baseline | 8.5 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 7.59 |
| Cohort 3 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Baseline | 183.8 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 448.83 |
| Cohort 3 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 3 | 270.4 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 585.78 |
| Cohort 3 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 6 | 242.7 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 449.4 |
| Cohort 3 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 9 | 59.0 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 98.77 |
| Cohort 4 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 3 | 100.2 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 154.91 |
| Cohort 4 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Baseline | 32.8 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 68.42 |
| Cohort 4 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 6 | 78.7 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 110.54 |
| Cohort 4 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 9 | 188.4 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 364.15 |
| Cohort 5 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 9 | 82.4 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 93.84 |
| Cohort 5 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 3 | 181.3 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 226.02 |
| Cohort 5 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Baseline | 19.2 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 32.88 |
| Cohort 5 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 6 | 214.4 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 191.11 |
| Cohort 6 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 6 | 27.6 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 64.34 |
| Cohort 6 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 9 | 10.3 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 13.29 |
| Cohort 6 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Week 3 | 9.0 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 18.73 |
| Cohort 6 | Immune Response Against CEA - IFN-gamma Secreting Cells by Visit | Baseline | 29.5 Spot-forming cells per 1,000,000 PBMC | Standard Deviation 44.96 |